In the other trials patients with NSCLC and EGFR mutation were pretreated with EGFR-TKIs (Aura 3, [35,42,47]), were chemotherapy naïve (Aspiration study [41,46]) and chemotherapy naïve for advanced disease (Eurtac [28], Insight study [37]). This evidence concerns the gene EGFR and non-small cell lung carcinoma.